Hi everybody. I’m Mikkael Sekeres, Director of the Leukemia Program at Cleveland Clinic, and I’m here to talk with you about higher-risk myelodysplastic syndromes.
When we talk about risk in myelodysplastic syndromes, we use as a default staging system the International Prognostic Scoring System, or IPSS. Patients with higher-risk disease under the IPSS may have multiple cytopenias, so anemia and neutropenia, or anemia and thrombocytopenia. They would have poor-risk cytogenetics, so either complex or abnormalities of chromosome 7, and they usually have a high blast percentage, 5-19%, where, of course, 20% would define patients as having acute myeloid leukemia.
We usually treat these patients with hypomethylating agents, such as azacitidine, decitabine, or the new oral decitabine, with azacitidine being the only one of those drugs that has shown a survival benefit in a prospective trial. And we offer bone marrow transplantation at diagnosis, as this is the only type of cure for MDS.
MANAGEMENT MINUTE EPISODE 1 TRANSCRIPT
Presented by Mikkael Sekeres, MD, MS
Director of the Leukemia Program at Cleveland Clinic and Vice Chair for Clinical Research at the Taussig Cancer Institute.